vaxgen,wahnsinn - 500 Beiträge pro Seite
eröffnet am 15.11.02 20:45:33 von
neuester Beitrag 05.09.03 23:21:31 von
neuester Beitrag 05.09.03 23:21:31 von
Beiträge: 32
ID: 660.897
ID: 660.897
Aufrufe heute: 0
Gesamt: 2.509
Gesamt: 2.509
Aktive User: 0
ISIN: US25245P2056 · WKN: A14V55
0,0140
EUR
0,00 %
0,0000 EUR
Letzter Kurs 11.04.17 Stuttgart
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,0920 | +167,10 | |
| 1,2500 | +92,01 | |
| 3,0380 | +75,15 | |
| 0,8905 | +74,51 | |
| 1,7900 | +35,61 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2029 | -14,15 | |
| 1,6100 | -15,26 | |
| 1,9600 | -16,24 | |
| 13,010 | -19,94 | |
| 3,5000 | -26,24 |
Feedback
BRISBANE, Calif., Nov. 14, 2002/PRNewswire-Firstcall über COMTEX/--
Vizepräsident Vaxgens von Unternehmenskommunikationen, Lanze Ignon,
stellt sich am upcoming finanziellen Mittagessen Gemeinschaft des
Friedland Kapitals für die Sicherheit, Schutz- u.
Verteidigungindustrie dar. Vaxgen ist der führende Entwickler der
vaccine Anwärter des AIDS und war vor kurzem die einzige VEREINIGTE
STAATEN Firma, die durch die VEREINIGTE STAATEN Regierung ausgewählt
wird, einen neuen Anthraximpfstoff zu entwickeln. Herr Ignon behandelt
vaccine Programm des Anthraxs Vaxgens und beschreibt, wie die Firma
Beendigung des ersten Phase III der Welt Versuches eines
AIDS-Impfstoffanwärters sich nähert. Phase III Versuche sind
gewöhnlich das abschließende Stadium der Entwicklung, bevor sie die
Genehmigung durch die zuständige Aufsichtsbehörde suchen.
Vizepräsident Vaxgens von Unternehmenskommunikationen, Lanze Ignon,
stellt sich am upcoming finanziellen Mittagessen Gemeinschaft des
Friedland Kapitals für die Sicherheit, Schutz- u.
Verteidigungindustrie dar. Vaxgen ist der führende Entwickler der
vaccine Anwärter des AIDS und war vor kurzem die einzige VEREINIGTE
STAATEN Firma, die durch die VEREINIGTE STAATEN Regierung ausgewählt
wird, einen neuen Anthraximpfstoff zu entwickeln. Herr Ignon behandelt
vaccine Programm des Anthraxs Vaxgens und beschreibt, wie die Firma
Beendigung des ersten Phase III der Welt Versuches eines
AIDS-Impfstoffanwärters sich nähert. Phase III Versuche sind
gewöhnlich das abschließende Stadium der Entwicklung, bevor sie die
Genehmigung durch die zuständige Aufsichtsbehörde suchen.
Time & Sales most recent back next
VAXGEN INC - Nasdaq National Market: VXGN
Rec. Time Action Price Volume Exch.
12:53:24 PM Ask 22.96 200 CIN
12:53:21 PM Ask 22.96 100 Nasdaq NM
12:53:16 PM Trade 22.969 500 Nasdaq NM
12:53:10 PM Ask 22.97 200 CIN
12:52:58 PM Ask 22.97 100 Nasdaq NM
12:52:58 PM Ask 22.98 200 CIN
12:52:54 PM Trade 22.9332 100 Nasdaq NM
12:52:47 PM Ask 22.98 400 CIN
12:52:45 PM Ask 22.98 200 CIN
12:52:42 PM Trade 22.98 200 Nasdaq NM
12:52:40 PM Ask 22.99 100 Nasdaq NM
12:52:36 PM Trade (at Ask) 23 100 Nasdaq NM
12:52:36 PM Ask 23 400 Nasdaq NM
12:52:35 PM Bid 22.8 100 Nasdaq NM
12:52:34 PM Trade (at Ask) 23 500 Nasdaq NM
12:52:34 PM Ask 23 500 Nasdaq NM
12:52:34 PM Ask 23.09 200 CIN
12:52:31 PM Trade 23.086 200 Nasdaq NM
12:52:31 PM Trade 23.08 200 Nasdaq NM
12:52:31 PM Ask 23 500 Nasdaq NM
VAXGEN INC - Nasdaq National Market: VXGN
Rec. Time Action Price Volume Exch.
12:53:24 PM Ask 22.96 200 CIN
12:53:21 PM Ask 22.96 100 Nasdaq NM
12:53:16 PM Trade 22.969 500 Nasdaq NM
12:53:10 PM Ask 22.97 200 CIN
12:52:58 PM Ask 22.97 100 Nasdaq NM
12:52:58 PM Ask 22.98 200 CIN
12:52:54 PM Trade 22.9332 100 Nasdaq NM
12:52:47 PM Ask 22.98 400 CIN
12:52:45 PM Ask 22.98 200 CIN
12:52:42 PM Trade 22.98 200 Nasdaq NM
12:52:40 PM Ask 22.99 100 Nasdaq NM
12:52:36 PM Trade (at Ask) 23 100 Nasdaq NM
12:52:36 PM Ask 23 400 Nasdaq NM
12:52:35 PM Bid 22.8 100 Nasdaq NM
12:52:34 PM Trade (at Ask) 23 500 Nasdaq NM
12:52:34 PM Ask 23 500 Nasdaq NM
12:52:34 PM Ask 23.09 200 CIN
12:52:31 PM Trade 23.086 200 Nasdaq NM
12:52:31 PM Trade 23.08 200 Nasdaq NM
12:52:31 PM Ask 23 500 Nasdaq NM
ist ja ein wildes rauf und runter. Hat jemand neuere Infos
was mit dem Laden los ist. Es war ja die Rede daß das Geld knapp wird
was mit dem Laden los ist. Es war ja die Rede daß das Geld knapp wird
Weiß denn keiner was mit dieser Gurke los ist
Trading Spotlight
04/07/2003 (10:41 ET) Wechsler Harwood LLP Files Class Action Lawsuit Against VaxGen, Inc. For False and Misleading Statements Regarding Vaccine Efficacy Rates For Certain Non-Caucasians -- VXGN - PrimeZone Media Network, Inc.
04/01/2003 (10:00 ET) VOLUME(-): VXGN Volume 12% > 20-adsv, Stock -22.63% - Knobias
04/01/2003 (09:54 ET) GAP-DN: Opening Lower UNWR, VXGN, GISH, RVSN, DDIC - Knobias
04/01/2003 (09:53 ET) 52W LOW: New 52-Wk Low for VXGN @ $2.110 dn30.59% - Knobias
04/01/2003 (09:27 ET) BID(-): VXGN Down After 10K Going Concern; Action Filed - Knobias
js200
04/01/2003 (10:00 ET) VOLUME(-): VXGN Volume 12% > 20-adsv, Stock -22.63% - Knobias
04/01/2003 (09:54 ET) GAP-DN: Opening Lower UNWR, VXGN, GISH, RVSN, DDIC - Knobias
04/01/2003 (09:53 ET) 52W LOW: New 52-Wk Low for VXGN @ $2.110 dn30.59% - Knobias
04/01/2003 (09:27 ET) BID(-): VXGN Down After 10K Going Concern; Action Filed - Knobias
js200
BID(-): VXGN Down After 10K Going Concern; Action Filed
Tuesday , April 01, 2003 09:27 ET
Shares of VaxGen Inc (NasdaqNM: VXGN) are bdding lower after a steep decline in late trading yesterday. This slide comes after a new 10-K filing revealed new "going concern statement" made by the Company`s auditor, KPMG.
According to the filing and it`s auditor report, "the Company has suffered recurring losses from operations during its development stage and expects to have a working capital deficiency for 2003 that raise substantial doubt about the Company`s ability to continue as a going concern".
In financial notes the VXGN stated:
"...in order for the Company to remain a going concern it will require significant additional funding in the near term...The Company expects the cash and cash equivalents at December 31, 2002, will be sufficient to fund operations according to its current plan through the third quarter of 2003..."
It also appears that this news was quickly followed by a class action suit filed by Schatz & Nobel, P.C. in the United States District Court for the Northern District of California.
Shares of VXGN are bidding as low as $2.20 after ending yesterday`s session at $3.04 after a late day slide from $3.50.
JS200
Tuesday , April 01, 2003 09:27 ET
Shares of VaxGen Inc (NasdaqNM: VXGN) are bdding lower after a steep decline in late trading yesterday. This slide comes after a new 10-K filing revealed new "going concern statement" made by the Company`s auditor, KPMG.
According to the filing and it`s auditor report, "the Company has suffered recurring losses from operations during its development stage and expects to have a working capital deficiency for 2003 that raise substantial doubt about the Company`s ability to continue as a going concern".
In financial notes the VXGN stated:
"...in order for the Company to remain a going concern it will require significant additional funding in the near term...The Company expects the cash and cash equivalents at December 31, 2002, will be sufficient to fund operations according to its current plan through the third quarter of 2003..."
It also appears that this news was quickly followed by a class action suit filed by Schatz & Nobel, P.C. in the United States District Court for the Northern District of California.
Shares of VXGN are bidding as low as $2.20 after ending yesterday`s session at $3.04 after a late day slide from $3.50.
JS200
Wechsler Harwood LLP Files Class Action Lawsuit Against VaxGen, Inc. For False and Misleading Statements Regarding Vaccine Efficacy Rates For Certain Non-Caucasians -- VXGN
Monday , April 07, 2003 10:41 ET
NEW YORK, Apr 07, 2003 (PRIMEZONE via COMTEX) -- Wechsler Harwood LLP today announced that a securities class action has been commenced on behalf of persons or entities who purchased or otherwise acquired the securities of VaxGen, Inc. ("VaxGen" or the "Company") (Nasdaq:VXGN) during the period between February 24, 2003 and February 26, 2003 (the "Class Period").
The case is pending in the United States District Court for the Northern District of California against defendants VaxGen and certain of its officers and directors. A copy of the complaint is available from the Court or can be viewed on the Wechsler Harwood web site at: www.whesq.com
VaxGen is engaged in the development and commercialization of AIDSVAX, a vaccine designed to prevent infection or disease caused by HIV (Human Immunodeficiency Virus), the virus that causes AIDS. The original AIDSVAX technology was developed by Genentech, Inc. and then licensed exclusively to the Company.
The Complaint alleges that on Sunday, February 23, 2003, the Company shocked the market by reporting that the long-awaited results of its U.S. clinical trials were a failure as the "study did not show a statistically significant reduction of HIV infection within the study population as a whole . . . the primary endpoint of the trial." On the following Monday morning, February 24, 2003, after trading was halted for an hour, VaxGen stock plummeted approximately 65%.
It is further alleged that by later that day, however, as the stock was still reeling from news of the failed clinical trials, defendants announced that the trials had actually demonstrated an efficacy rate in the range of 30% to 84% for an ethnic subgroup of non-Caucasian, non-Hispanic volunteers and that the vaccine could be approved for such populations. Upon this encouraging news, the VaxGen stock shot back up nearly 130% from the trading day low of $3.00 to over $7.60 per share.
Nonetheless, two days later, on February 26, 2003, defendants again shocked the investing community by revealing that the statements regarding elevated efficacy rates for non-Caucasians were inaccurate and unsubstantiated because the Company had not taken the necessary "penalties" to account for the fact that less than 10% of the clinical trial participants were actually non-Caucasians. On this news, VaxGen stock again plummeted to a close of $4.82 per share and progressively lost value thereafter. As of April 3, 2003, shares of VaxGen were trading at approximately $2.50 per share.
If you purchased securities during the Class Period, you may, no later than June 6, 2003, move to be appointed as a lead plaintiff in this class action. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member`s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Under certain circumstances, one or more class members may together serve as lead plaintiff. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. You may retain Wechsler Harwood, or other counsel of your choice, to serve as your counsel in this action.
Wechsler Harwood has taken a leading role in many important actions on behalf of defrauded shareholders. The Wechsler Harwood website (www.whesq.com) has more information about the firm and detailed information regarding this matter. If you wish to discuss this action with us, or have any questions concerning this notice or your rights and interests with regard to the case, please contact the following:
Wechsler Harwood LLP
488 Madison Avenue, 8th Floor
New York, New York 10022
Phone: 877-935-7400 (Toll Free)
David Leifer, Wechsler Harwood Shareholder Relations Department:
dleifer@whesq.com, extension-251
More information on this and other class actions can be found on the Class Action Newsline at www.primezone.com/ca
By Staff
CONTACT: Wechsler Harwood LLP
David Leifer
(877) 935-7400
(C) 2003 PRIMEZONE, All rights reserved.
-0-
INDUSTRY KEYWORD: Legal Services
SUBJECT CODE: CLASS ACTION LAWSUITS
Law & Legal Issues
JS200
Monday , April 07, 2003 10:41 ET
NEW YORK, Apr 07, 2003 (PRIMEZONE via COMTEX) -- Wechsler Harwood LLP today announced that a securities class action has been commenced on behalf of persons or entities who purchased or otherwise acquired the securities of VaxGen, Inc. ("VaxGen" or the "Company") (Nasdaq:VXGN) during the period between February 24, 2003 and February 26, 2003 (the "Class Period").
The case is pending in the United States District Court for the Northern District of California against defendants VaxGen and certain of its officers and directors. A copy of the complaint is available from the Court or can be viewed on the Wechsler Harwood web site at: www.whesq.com
VaxGen is engaged in the development and commercialization of AIDSVAX, a vaccine designed to prevent infection or disease caused by HIV (Human Immunodeficiency Virus), the virus that causes AIDS. The original AIDSVAX technology was developed by Genentech, Inc. and then licensed exclusively to the Company.
The Complaint alleges that on Sunday, February 23, 2003, the Company shocked the market by reporting that the long-awaited results of its U.S. clinical trials were a failure as the "study did not show a statistically significant reduction of HIV infection within the study population as a whole . . . the primary endpoint of the trial." On the following Monday morning, February 24, 2003, after trading was halted for an hour, VaxGen stock plummeted approximately 65%.
It is further alleged that by later that day, however, as the stock was still reeling from news of the failed clinical trials, defendants announced that the trials had actually demonstrated an efficacy rate in the range of 30% to 84% for an ethnic subgroup of non-Caucasian, non-Hispanic volunteers and that the vaccine could be approved for such populations. Upon this encouraging news, the VaxGen stock shot back up nearly 130% from the trading day low of $3.00 to over $7.60 per share.
Nonetheless, two days later, on February 26, 2003, defendants again shocked the investing community by revealing that the statements regarding elevated efficacy rates for non-Caucasians were inaccurate and unsubstantiated because the Company had not taken the necessary "penalties" to account for the fact that less than 10% of the clinical trial participants were actually non-Caucasians. On this news, VaxGen stock again plummeted to a close of $4.82 per share and progressively lost value thereafter. As of April 3, 2003, shares of VaxGen were trading at approximately $2.50 per share.
If you purchased securities during the Class Period, you may, no later than June 6, 2003, move to be appointed as a lead plaintiff in this class action. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member`s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Under certain circumstances, one or more class members may together serve as lead plaintiff. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. You may retain Wechsler Harwood, or other counsel of your choice, to serve as your counsel in this action.
Wechsler Harwood has taken a leading role in many important actions on behalf of defrauded shareholders. The Wechsler Harwood website (www.whesq.com) has more information about the firm and detailed information regarding this matter. If you wish to discuss this action with us, or have any questions concerning this notice or your rights and interests with regard to the case, please contact the following:
Wechsler Harwood LLP
488 Madison Avenue, 8th Floor
New York, New York 10022
Phone: 877-935-7400 (Toll Free)
David Leifer, Wechsler Harwood Shareholder Relations Department:
dleifer@whesq.com, extension-251
More information on this and other class actions can be found on the Class Action Newsline at www.primezone.com/ca
By Staff
CONTACT: Wechsler Harwood LLP
David Leifer
(877) 935-7400
(C) 2003 PRIMEZONE, All rights reserved.
-0-
INDUSTRY KEYWORD: Legal Services
SUBJECT CODE: CLASS ACTION LAWSUITS
Law & Legal Issues
JS200
RAiDAR alerts Learn More About RAiDAR-LT
04/07/2003 (10:41 ET) Wechsler Harwood LLP Files Class Action Lawsuit Against VaxGen, Inc. For False and Misleading Statements Regarding Vaccine Efficacy Rates For Certain Non-Caucasians -- VXGN - PrimeZone Media Network, Inc.
04/01/2003 (10:00 ET) VOLUME(-): VXGN Volume 12% > 20-adsv, Stock -22.63% - Knobias
04/01/2003 (09:54 ET) GAP-DN: Opening Lower UNWR, VXGN, GISH, RVSN, DDIC - Knobias
04/01/2003 (09:53 ET) 52W LOW: New 52-Wk Low for VXGN @ $2.110 dn30.59% - Knobias
04/01/2003 (09:27 ET) BID(-): VXGN Down After 10K Going Concern; Action Filed - Knobias
03/31/2003 (18:46 ET) Schatz & Nobel, P.C. Announces Class Action Lawsuit Against VaxGen, Inc. - PR Newswire
03/31/2003 (16:16 ET) New 10-K just released for VXGN - Edgar
03/31/2003 (11:59 ET) HIV/Aids: The Cure Alternatives - Africa News Service
03/28/2003 (11:00 ET) VaxGen to Provide Webcast of Keystone Symposia Presentation - PR Newswire
03/27/2003 (12:58 ET) Wolf Haldenstein Adler Freeman and Herz LLP Commences VaxGen Class Action - PR Newswire
03/27/2003 (06:31 ET) MEDIA: Today`s Wall Street Journal Mentions VXGN - Knobias
03/26/2003 (17:29 ET) New 424B3 just released for VXGN - Edgar
03/24/2003 (18:57 ET) Johnson & Perkinson Announces Class Action Lawsuit Against VaxGen, Inc. - Business Wire
03/20/2003 (12:55 ET) Cauley Geller Announces Class Action Lawsuit Against VaxGen, Inc. on Behalf of Investors - PR Newswire
03/20/2003 (11:21 ET) Law Offices of Brodsky & Smith, LLC Announces Class Action Lawsuit Against VaxGen, Inc. -- VXGN - PrimeZone Media Network, Inc.
03/20/2003 (10:50 ET) Shareholder Class Action Filed Against Vaxgen Inc. by the Law Firm of Schiffrin & Barroway, LLP -- VXGN - PrimeZone Media Network, Inc.
03/19/2003 (14:33 ET) Law Offices of Charles J. Piven, P.A. Announces Class Action Lawsuit Against VaxGen, Inc. - Internet Wire
03/19/2003 (08:07 ET) New 8-K just released for VXGN - Edgar
03/19/2003 (07:02 ET) CONF: VXGN To Present At SG Cowen Health Care Conference @ 08:00 ET - Knobias
03/19/2003 (07:02 ET) CONF: VXGN To Present At SG Cowen Health Care Conference @ 09:00 ET - Knobias
03/18/2003 (11:04 ET) EquityOutlook.Com: EquityOutlook.Com announces Stock Evaluation Ratings for Chevron Texaco, Dreyer`s Grand Ice Cream, Teco Energy Inc, Vaxgen Inc, Barrick Gold Corp - M2 Communications
03/17/2003 (20:02 ET) ELEVENTH Business Wire recap for Monday (March 17); stories sent between 18:01 and 19:00 ET (15:01 and 16:00 PT) - Business Wire
03/17/2003 (18:01 ET) Milberg Weiss Files Class Action Suit Against VaxGen Inc. - Business Wire
03/13/2003 (17:49 ET) VaxGen Stock Soars on Improved Forecast - Associated Press Online
03/13/2003 (16:54 ET) New 8-K just released for VXGN - Edgar
company profile
Formed to complete the development of AIDSVAX®, a vaccine designed to prevent infection or disease caused by HIV (Human Immunodeficiency Virus), the virus that causes AIDS. ... MORE INFO
CONTACT: Lance K. Gordon (CEO)
JS200
04/07/2003 (10:41 ET) Wechsler Harwood LLP Files Class Action Lawsuit Against VaxGen, Inc. For False and Misleading Statements Regarding Vaccine Efficacy Rates For Certain Non-Caucasians -- VXGN - PrimeZone Media Network, Inc.
04/01/2003 (10:00 ET) VOLUME(-): VXGN Volume 12% > 20-adsv, Stock -22.63% - Knobias
04/01/2003 (09:54 ET) GAP-DN: Opening Lower UNWR, VXGN, GISH, RVSN, DDIC - Knobias
04/01/2003 (09:53 ET) 52W LOW: New 52-Wk Low for VXGN @ $2.110 dn30.59% - Knobias
04/01/2003 (09:27 ET) BID(-): VXGN Down After 10K Going Concern; Action Filed - Knobias
03/31/2003 (18:46 ET) Schatz & Nobel, P.C. Announces Class Action Lawsuit Against VaxGen, Inc. - PR Newswire
03/31/2003 (16:16 ET) New 10-K just released for VXGN - Edgar
03/31/2003 (11:59 ET) HIV/Aids: The Cure Alternatives - Africa News Service
03/28/2003 (11:00 ET) VaxGen to Provide Webcast of Keystone Symposia Presentation - PR Newswire
03/27/2003 (12:58 ET) Wolf Haldenstein Adler Freeman and Herz LLP Commences VaxGen Class Action - PR Newswire
03/27/2003 (06:31 ET) MEDIA: Today`s Wall Street Journal Mentions VXGN - Knobias
03/26/2003 (17:29 ET) New 424B3 just released for VXGN - Edgar
03/24/2003 (18:57 ET) Johnson & Perkinson Announces Class Action Lawsuit Against VaxGen, Inc. - Business Wire
03/20/2003 (12:55 ET) Cauley Geller Announces Class Action Lawsuit Against VaxGen, Inc. on Behalf of Investors - PR Newswire
03/20/2003 (11:21 ET) Law Offices of Brodsky & Smith, LLC Announces Class Action Lawsuit Against VaxGen, Inc. -- VXGN - PrimeZone Media Network, Inc.
03/20/2003 (10:50 ET) Shareholder Class Action Filed Against Vaxgen Inc. by the Law Firm of Schiffrin & Barroway, LLP -- VXGN - PrimeZone Media Network, Inc.
03/19/2003 (14:33 ET) Law Offices of Charles J. Piven, P.A. Announces Class Action Lawsuit Against VaxGen, Inc. - Internet Wire
03/19/2003 (08:07 ET) New 8-K just released for VXGN - Edgar
03/19/2003 (07:02 ET) CONF: VXGN To Present At SG Cowen Health Care Conference @ 08:00 ET - Knobias
03/19/2003 (07:02 ET) CONF: VXGN To Present At SG Cowen Health Care Conference @ 09:00 ET - Knobias
03/18/2003 (11:04 ET) EquityOutlook.Com: EquityOutlook.Com announces Stock Evaluation Ratings for Chevron Texaco, Dreyer`s Grand Ice Cream, Teco Energy Inc, Vaxgen Inc, Barrick Gold Corp - M2 Communications
03/17/2003 (20:02 ET) ELEVENTH Business Wire recap for Monday (March 17); stories sent between 18:01 and 19:00 ET (15:01 and 16:00 PT) - Business Wire
03/17/2003 (18:01 ET) Milberg Weiss Files Class Action Suit Against VaxGen Inc. - Business Wire
03/13/2003 (17:49 ET) VaxGen Stock Soars on Improved Forecast - Associated Press Online
03/13/2003 (16:54 ET) New 8-K just released for VXGN - Edgar
company profile
Formed to complete the development of AIDSVAX®, a vaccine designed to prevent infection or disease caused by HIV (Human Immunodeficiency Virus), the virus that causes AIDS. ... MORE INFO
CONTACT: Lance K. Gordon (CEO)
JS200
@FRANK 55
Genügt dir das fürs erste ????
JS200
Genügt dir das fürs erste ????
JS200
@FRANK 55
Ein TOTALER MISSERFOLG
VaxGen`s shares surged $1.37, or 49.6 percent, to close Thursday at $4.13 each on the Nasdaq Stock Market. The company`s stock has plummeted from a 52-week high of $23.25 and has been dropping consistently since it announced last month that its AIDS vaccine experiment was mostly a failure.
JS200
Ein TOTALER MISSERFOLG
VaxGen`s shares surged $1.37, or 49.6 percent, to close Thursday at $4.13 each on the Nasdaq Stock Market. The company`s stock has plummeted from a 52-week high of $23.25 and has been dropping consistently since it announced last month that its AIDS vaccine experiment was mostly a failure.
JS200
danke JS222 für die Infos. Mir ist die Kiste jetzt zu heiß und hab die Dinger mit Verlust rausgeworfen.
Lieber ein Ende mit Schrecken als ein Schrecken ohne Ende
Lieber ein Ende mit Schrecken als ein Schrecken ohne Ende
@MISTKATER
Gerngeschehen, hatte sonst nichts zu tun
JS200
Gerngeschehen, hatte sonst nichts zu tun
JS200
Richtig,Verluste rechtzeitig begrenzen,Gewinne laufen lassen,da dieser Impfstoff scheinbar nur bei einer bestimmten Anzahl von Asiaten und Afrikaner zu wirken scheint,bin schon bei 20 $ wieder raus
Scott + Scott, LLC Announces Class Action Lawsuit Against VaxGen
via COMTEX
April 23, 2003
COLCHESTER, Conn., Apr 23, 2003 (BUSINESS WIRE) --
VaxGen, Inc. Shareholder Lawsuit Brought by Scott + Scott, LLC.
Scott + Scott, LLC (scottlaw@scott-scott.com), a Connecticut- based law firm, announced that it has commenced a class action in the United States District Court for the Northern District of California on behalf of purchasers of VaxGen, Inc. (`VaxGen`or the `Company`) (Nasdaq: VXGN) publicly traded securities during the period between August 6, 2002 and February 26, 2003, inclusive (the `Class Period`). A copy of the complaint filed in this action on behalf of an investor is available from the Court or can be obtained by calling Scott + Scott, LLC at 800/404-7770, e-mailing the firm at nrothstein@scott-scott.com or by going to the Web Site at http://www.scott-scott.com. For more information, you can also contact attorney Neil Rothstein at nrothstein@scott-scott.com.
If you wish to serve as lead plaintiff and if you bought VaxGen publicly traded securities between August 6, 2002 and February 26, 2003, inclusive, and you wish to serve as lead plaintiff, you must move the Court no later than May 16, 2003. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. Any member of the purported class may move the Court to serve as lead plaintiff through Scott + Scott, LLC or through counsel of their choice, or may choose to do nothing and remain an absent class member. In order to be appointed lead plaintiff, you must meet certain legal requirements. Please be aware that Scott + Scott, LLC has filed this lawsuit at the request of shareholders.
The complaint charges VaxGen and certain of its officers and directors with issuing materially false and misleading statements concerning its business and financial condition. VaxGen is engaged in the development and commercialization of AIDSVAX, a vaccine designed to prevent infection or disease caused by HIV (Human Immunodeficiency Virus), the virus that causes AIDS. During the Class Period, defendants were completing the final stages of AIDSVAX`s Phase III clinical trials required to obtain Food and Drug Administration approval to market AIDSVAX as an AIDS vaccine. Throughout the Class Period, defendants caused VaxGen to make a number of positive statements about the status of the trial and describing their eventual plans to manufacture and market AIDSVAX, causing VaxGen`s stock to trade at artificially inflated prices.
On Feb. 26, 2003, however, defendants were forced to admit that the reliability of their earlier reports of higher efficacy rates for non- caucasians were impaired because they had not taken the requisite `penalties`to account for the fact that less than 500 of the 5000 clinical trial participants were non-caucasians, resulting in an extremely small subset of data being analyzed for non-caucasians. As the news that earlier promises that AIDSVAX could prove useful for non-caucasians fell apart, the stock declined further, resulting in a total loss in market cap since Nov. 18, 2002 of approximately 85%.
Plaintiff seeks to recover damages on behalf of all purchasers of VaxGen`s stock during the Class Period (the `Class`).
Scott + Scott, LLC is a Connecticut-based law firm engaged in the representation of funds, foundations, endowments, institutions, pension funds, individuals and other entities throughout the world in securities, antitrust and other complex class and non-class action litigation. The firm is committed to client satisfaction and communication. The firm`s attorneys litigate in both state and federal courts throughout the nation. The firm has been appointed lead counsel on cases nationwide, including the ongoing Imclone Securities Litigation. Scott + Scott, LLC issues this release in accordance with the applicable federal securities laws. If you wish to discuss this action, have any questions concerning this notice, your rights with respect to this matter or any other securities fraud matter (including recently filed class actions against Electro Scientific Industries, Accredo, Cerner Corp.,Supergen, Inc. Affymetrix Corp. or Ultimate Electronics) please contact David R. Scott, Esq., drscott@scott-scott.com or Neil Rothstein, Esq., nrothstein@scott-scott.com, Scott + Scott, LLC, 108 Norwich Avenue, Colchester, Connecticut 06415 at 800/404-7770. Fax: 860/537-4432.
Scott + Scott, LLC David R. Scott, Esq., drscott@scott-scott.com Neil Rothstein, Esq., nrothstein@scott-scott.com 800/404-7770 Fax: 860/537-4432 TICKERS: NASDAQ: VXGN
http://www.businesswire.com
Today`s News On The Net - Business Wire`s full file on the Internet with Hyperlinks to your home page.
Copyright (C) 2003 Business Wire. All rights reserved.
JS200
via COMTEX
April 23, 2003
COLCHESTER, Conn., Apr 23, 2003 (BUSINESS WIRE) --
VaxGen, Inc. Shareholder Lawsuit Brought by Scott + Scott, LLC.
Scott + Scott, LLC (scottlaw@scott-scott.com), a Connecticut- based law firm, announced that it has commenced a class action in the United States District Court for the Northern District of California on behalf of purchasers of VaxGen, Inc. (`VaxGen`or the `Company`) (Nasdaq: VXGN) publicly traded securities during the period between August 6, 2002 and February 26, 2003, inclusive (the `Class Period`). A copy of the complaint filed in this action on behalf of an investor is available from the Court or can be obtained by calling Scott + Scott, LLC at 800/404-7770, e-mailing the firm at nrothstein@scott-scott.com or by going to the Web Site at http://www.scott-scott.com. For more information, you can also contact attorney Neil Rothstein at nrothstein@scott-scott.com.
If you wish to serve as lead plaintiff and if you bought VaxGen publicly traded securities between August 6, 2002 and February 26, 2003, inclusive, and you wish to serve as lead plaintiff, you must move the Court no later than May 16, 2003. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. Any member of the purported class may move the Court to serve as lead plaintiff through Scott + Scott, LLC or through counsel of their choice, or may choose to do nothing and remain an absent class member. In order to be appointed lead plaintiff, you must meet certain legal requirements. Please be aware that Scott + Scott, LLC has filed this lawsuit at the request of shareholders.
The complaint charges VaxGen and certain of its officers and directors with issuing materially false and misleading statements concerning its business and financial condition. VaxGen is engaged in the development and commercialization of AIDSVAX, a vaccine designed to prevent infection or disease caused by HIV (Human Immunodeficiency Virus), the virus that causes AIDS. During the Class Period, defendants were completing the final stages of AIDSVAX`s Phase III clinical trials required to obtain Food and Drug Administration approval to market AIDSVAX as an AIDS vaccine. Throughout the Class Period, defendants caused VaxGen to make a number of positive statements about the status of the trial and describing their eventual plans to manufacture and market AIDSVAX, causing VaxGen`s stock to trade at artificially inflated prices.
On Feb. 26, 2003, however, defendants were forced to admit that the reliability of their earlier reports of higher efficacy rates for non- caucasians were impaired because they had not taken the requisite `penalties`to account for the fact that less than 500 of the 5000 clinical trial participants were non-caucasians, resulting in an extremely small subset of data being analyzed for non-caucasians. As the news that earlier promises that AIDSVAX could prove useful for non-caucasians fell apart, the stock declined further, resulting in a total loss in market cap since Nov. 18, 2002 of approximately 85%.
Plaintiff seeks to recover damages on behalf of all purchasers of VaxGen`s stock during the Class Period (the `Class`).
Scott + Scott, LLC is a Connecticut-based law firm engaged in the representation of funds, foundations, endowments, institutions, pension funds, individuals and other entities throughout the world in securities, antitrust and other complex class and non-class action litigation. The firm is committed to client satisfaction and communication. The firm`s attorneys litigate in both state and federal courts throughout the nation. The firm has been appointed lead counsel on cases nationwide, including the ongoing Imclone Securities Litigation. Scott + Scott, LLC issues this release in accordance with the applicable federal securities laws. If you wish to discuss this action, have any questions concerning this notice, your rights with respect to this matter or any other securities fraud matter (including recently filed class actions against Electro Scientific Industries, Accredo, Cerner Corp.,Supergen, Inc. Affymetrix Corp. or Ultimate Electronics) please contact David R. Scott, Esq., drscott@scott-scott.com or Neil Rothstein, Esq., nrothstein@scott-scott.com, Scott + Scott, LLC, 108 Norwich Avenue, Colchester, Connecticut 06415 at 800/404-7770. Fax: 860/537-4432.
Scott + Scott, LLC David R. Scott, Esq., drscott@scott-scott.com Neil Rothstein, Esq., nrothstein@scott-scott.com 800/404-7770 Fax: 860/537-4432 TICKERS: NASDAQ: VXGN
http://www.businesswire.com
Today`s News On The Net - Business Wire`s full file on the Internet with Hyperlinks to your home page.
Copyright (C) 2003 Business Wire. All rights reserved.
JS200
Man soll ja nicht schadenfroh sein
aber wer heut in Frankfurt 1100 St zu 3,70 gekauft hat
muß ein bißerl ein Dilo sein
aber wer heut in Frankfurt 1100 St zu 3,70 gekauft hat
muß ein bißerl ein Dilo sein
Aber der Kurs scheint sich
wieder aufzubauen.
wieder aufzubauen.
#19
Aber immer im Dreiwochen-
rhythmus,um dann noch vor
2USD zu stoppen.Wenn die
Stützung fehlen sollte...
Grüße
Aber immer im Dreiwochen-
rhythmus,um dann noch vor
2USD zu stoppen.Wenn die
Stützung fehlen sollte...
Grüße
.
Deutsche Aktionäre haben eine neue Methode entwickelt: Durchtauchen
Fällt mir ein bei 3,24US / 2,50EU
Deutsche Aktionäre haben eine neue Methode entwickelt: Durchtauchen
Fällt mir ein bei 3,24US / 2,50EU
Die vertrottelste Taxerei die ich kenn ist VXGN / Frankfurt
Heute wieder 3,21 US / 2,65 EU. Soll hier ein neuer Währungskurs geschaffen werden ?
Heute wieder 3,21 US / 2,65 EU. Soll hier ein neuer Währungskurs geschaffen werden ?
FDA Clears VaxGen`s IND for Anthrax Vaccine Candidate; Clinical Development to Begin at Leading Medical Centers [INLINE]
via CDS
May 27, 2003
BRISBANE, Calif., May 27 /PRNewswire-FirstCall/ -- VaxGen, Inc. (Nasdaq: VXGN) announced today that the U.S. Food and Drug Administration has cleared the Investigational New Drug (IND) application for its candidate anthrax vaccine.
(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO )
The effective IND allows VaxGen to begin clinical development of the investigational vaccine with the goal of producing an emergency stockpile for the U.S. government and licensing the product for commercial sales. The next step in this process will be the initiation of a Phase I human clinical trial involving approximately 100 volunteers at four leading medical centers: Baylor College of Medicine in Houston, Emory University School of Medicine in Atlanta, Johns Hopkins University in Baltimore and Saint Louis University Health Sciences Center.
The trial will evaluate the safety and immunogenicity of VaxGen`s candidate vaccine compared to those of the existing licensed anthrax vaccine. The vaccine candidate`s efficacy will be established by comparing the immune responses in humans to those shown to protect animals from inhalation of anthrax spores.
The Phase I trial is being funded through VaxGen`s contract, N01-AI-25494, with the National Institute of Allergy and Infectious Disease (NIAID), a component of the National Institutes of Health. The purpose of the project is to develop an anthrax vaccine that is safe in humans, efficacious in animal inhalation challenge studies and requires no more than three injections, compared to the six injections required with the existing licensed anthrax vaccine. The contract calls for the vaccine to be made from recombinant Protective Antigen (rPA), a protein known to induce antibodies that neutralize anthrax toxins. Achieving full licensure will depend on the results of current and planned studies designed to satisfy the standard requirements for
FDA vaccine licensure, with the exception that the demonstration of efficacy will be in animals according to the FDA`s `Animal Rule,`published in the Federal Register on May 31, 2002.
`The ability to begin Phase I clinical trials advances our ultimate goal of supplying the next-generation anthrax vaccine to the U.S. and foreign governments, as well as private markets,`said Lance K. Gordon, Ph.D., VaxGen`s chief executive officer. `Since winning our anthrax contract, VaxGen has overseen the manufacture of more than 2,000 doses of vaccine available for clinical studies, completed all required pre-IND development and cleared an IND. This is a remarkable record of achievement that we believe demonstrates VaxGen`s ability to manage complex projects under tight deadlines and to satisfy the regulatory and contract requirements of the program.`
VaxGen expects the U.S. government to award two additional anthrax vaccine contracts later this year.
On May 23, NIAID issued a request for proposals (RFP DMID-03-29) for advanced development of an rPA anthrax vaccine candidate. Deliverables under this new contract are to include the manufacture of 3-to-5 million doses as well as much of the preclinical and clinical testing necessary for submission of a license application to the FDA. VaxGen is already required under its existing NIAID contract to submit a plan for manufacturing 25 million doses for use in the case of an emergency under an active IND.
VaxGen expects that the Department of Health and Human Services and/or the Department of Homeland Defense will issue a separate contract for a stockpile of 25 million doses.
VaxGen intends to produce the vaccine candidate at its manufacturing facility in South San Francisco if it wins the advanced-development contract and/or the stockpile contract.
VaxGen`s anthrax vaccine candidate is based on the pioneering work of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), and is being developed through collaboration with Battelle Memorial Institute, Columbus, Ohio. The vaccine combines the potential safety benefits of a product made through modern recombinant technology with demonstrated efficacy in animal models. Made through genetic engineering, the vaccine candidate is composed of an alum adjuvant and a purified protein (rPA) designed to induce antibodies that neutralize anthrax toxins. The vaccine candidate cannot cause anthrax infection.
About VaxGen
VaxGen, Inc. is a biopharmaceutical company engaged in the development, manufacture and commercialization of biologic products for the prevention and treatment of human infectious disease. Based in Brisbane, Calif., the company is developing preventive vaccines against anthrax, smallpox and HIV/AIDS and is the largest shareholder in Celltrion, Inc., a joint venture formed to build operations for the manufacture of biopharmaceutical products, including VaxGen`s vaccine candidates, should they be licensed. For more information, please visit the company`s web site at: http://www.vaxgen.com
NOTE: AIDSVAX(R) is a registered trademark of VaxGen.
Note: This press release contains `forward-looking statements`within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the timing and progress of completion of development efforts for VaxGen`s anthrax vaccine candidate; VaxGen`s ability to secure additional U.S. government anthrax vaccine contracts; the ability to launch and complete Phase I clinical trials for the anthrax vaccine candidate; the timing and scope of future contracts with the U.S. government; and the criteria used by the U.S. government in determining whether to award future contracts. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Reference should be made to VaxGen`s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on May 15, 2003, under the heading `Risk Factors`, and the company`s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 31, 2003, under the heading `Business`for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward- looking statements that speak only as of the date of this release. VaxGen undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.
JS200
via CDS
May 27, 2003
BRISBANE, Calif., May 27 /PRNewswire-FirstCall/ -- VaxGen, Inc. (Nasdaq: VXGN) announced today that the U.S. Food and Drug Administration has cleared the Investigational New Drug (IND) application for its candidate anthrax vaccine.
(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO )
The effective IND allows VaxGen to begin clinical development of the investigational vaccine with the goal of producing an emergency stockpile for the U.S. government and licensing the product for commercial sales. The next step in this process will be the initiation of a Phase I human clinical trial involving approximately 100 volunteers at four leading medical centers: Baylor College of Medicine in Houston, Emory University School of Medicine in Atlanta, Johns Hopkins University in Baltimore and Saint Louis University Health Sciences Center.
The trial will evaluate the safety and immunogenicity of VaxGen`s candidate vaccine compared to those of the existing licensed anthrax vaccine. The vaccine candidate`s efficacy will be established by comparing the immune responses in humans to those shown to protect animals from inhalation of anthrax spores.
The Phase I trial is being funded through VaxGen`s contract, N01-AI-25494, with the National Institute of Allergy and Infectious Disease (NIAID), a component of the National Institutes of Health. The purpose of the project is to develop an anthrax vaccine that is safe in humans, efficacious in animal inhalation challenge studies and requires no more than three injections, compared to the six injections required with the existing licensed anthrax vaccine. The contract calls for the vaccine to be made from recombinant Protective Antigen (rPA), a protein known to induce antibodies that neutralize anthrax toxins. Achieving full licensure will depend on the results of current and planned studies designed to satisfy the standard requirements for
FDA vaccine licensure, with the exception that the demonstration of efficacy will be in animals according to the FDA`s `Animal Rule,`published in the Federal Register on May 31, 2002.
`The ability to begin Phase I clinical trials advances our ultimate goal of supplying the next-generation anthrax vaccine to the U.S. and foreign governments, as well as private markets,`said Lance K. Gordon, Ph.D., VaxGen`s chief executive officer. `Since winning our anthrax contract, VaxGen has overseen the manufacture of more than 2,000 doses of vaccine available for clinical studies, completed all required pre-IND development and cleared an IND. This is a remarkable record of achievement that we believe demonstrates VaxGen`s ability to manage complex projects under tight deadlines and to satisfy the regulatory and contract requirements of the program.`
VaxGen expects the U.S. government to award two additional anthrax vaccine contracts later this year.
On May 23, NIAID issued a request for proposals (RFP DMID-03-29) for advanced development of an rPA anthrax vaccine candidate. Deliverables under this new contract are to include the manufacture of 3-to-5 million doses as well as much of the preclinical and clinical testing necessary for submission of a license application to the FDA. VaxGen is already required under its existing NIAID contract to submit a plan for manufacturing 25 million doses for use in the case of an emergency under an active IND.
VaxGen expects that the Department of Health and Human Services and/or the Department of Homeland Defense will issue a separate contract for a stockpile of 25 million doses.
VaxGen intends to produce the vaccine candidate at its manufacturing facility in South San Francisco if it wins the advanced-development contract and/or the stockpile contract.
VaxGen`s anthrax vaccine candidate is based on the pioneering work of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), and is being developed through collaboration with Battelle Memorial Institute, Columbus, Ohio. The vaccine combines the potential safety benefits of a product made through modern recombinant technology with demonstrated efficacy in animal models. Made through genetic engineering, the vaccine candidate is composed of an alum adjuvant and a purified protein (rPA) designed to induce antibodies that neutralize anthrax toxins. The vaccine candidate cannot cause anthrax infection.
About VaxGen
VaxGen, Inc. is a biopharmaceutical company engaged in the development, manufacture and commercialization of biologic products for the prevention and treatment of human infectious disease. Based in Brisbane, Calif., the company is developing preventive vaccines against anthrax, smallpox and HIV/AIDS and is the largest shareholder in Celltrion, Inc., a joint venture formed to build operations for the manufacture of biopharmaceutical products, including VaxGen`s vaccine candidates, should they be licensed. For more information, please visit the company`s web site at: http://www.vaxgen.com
NOTE: AIDSVAX(R) is a registered trademark of VaxGen.
Note: This press release contains `forward-looking statements`within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the timing and progress of completion of development efforts for VaxGen`s anthrax vaccine candidate; VaxGen`s ability to secure additional U.S. government anthrax vaccine contracts; the ability to launch and complete Phase I clinical trials for the anthrax vaccine candidate; the timing and scope of future contracts with the U.S. government; and the criteria used by the U.S. government in determining whether to award future contracts. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Reference should be made to VaxGen`s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on May 15, 2003, under the heading `Risk Factors`, and the company`s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 31, 2003, under the heading `Business`for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward- looking statements that speak only as of the date of this release. VaxGen undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.
JS200
Diese Passagen werden vermutlich demnächst dafür sorgen, dass es aufwärts geht.
FDA Clears VaxGen`s IND for Anthrax Vaccine Candidate; Clinical Development to Begin at Leading Medical Centers [INLINE] via CDS May 27, 2003
BRISBANE, Calif., May 27 /PRNewswire-FirstCall/ -- VaxGen, Inc. (Nasdaq: VXGN) announced today that the U.S. Food and Drug Administration has cleared the Investigational New Drug (IND) application for its candidate anthrax vaccine.
VaxGen expects the U.S. government to award two additional anthrax vaccine contracts later this year.
On May 23, NIAID issued a request for proposals (RFP DMID-03-29) for advanced development of an rPA anthrax vaccine candidate. Deliverables under this new contract are to include the manufacture of 3-to-5 million doses as well as much of the preclinical and clinical testing necessary for submission of a license application to the FDA. VaxGen is already required under its existing NIAID contract to submit a plan for manufacturing 25 million doses for use in the case of an emergency under an active IND.
FDA Clears VaxGen`s IND for Anthrax Vaccine Candidate; Clinical Development to Begin at Leading Medical Centers [INLINE] via CDS May 27, 2003
BRISBANE, Calif., May 27 /PRNewswire-FirstCall/ -- VaxGen, Inc. (Nasdaq: VXGN) announced today that the U.S. Food and Drug Administration has cleared the Investigational New Drug (IND) application for its candidate anthrax vaccine.
VaxGen expects the U.S. government to award two additional anthrax vaccine contracts later this year.
On May 23, NIAID issued a request for proposals (RFP DMID-03-29) for advanced development of an rPA anthrax vaccine candidate. Deliverables under this new contract are to include the manufacture of 3-to-5 million doses as well as much of the preclinical and clinical testing necessary for submission of a license application to the FDA. VaxGen is already required under its existing NIAID contract to submit a plan for manufacturing 25 million doses for use in the case of an emergency under an active IND.
Habe mir heute mal wieder ein paar gekauft, einfach so 
. Gibt es aktuelle Meinungen zu VXGN??
Greetinxx Heinerle2
. Gibt es aktuelle Meinungen zu VXGN??Greetinxx Heinerle2
Hast punktgenau einen Treffer gelandet !
Gestern kam ne Meldung nachbörslich.
Und der Kurs ging auf 6,77 USD !
Die Aktien von VaxGen konnten heute abend um 44% zulegen nach dem der amerikanische Hersteller von flüssigen Medikamenten verkündete, dass man mit britischen Behörden darüber verhandle, wann man die Vermarktungs- und Lizenzrechte für ein Medikamenten gegen Anthrax erhalten könne. Man rechne mit einer baldigen Entscheidung.
Gestern kam ne Meldung nachbörslich.
Und der Kurs ging auf 6,77 USD !
Die Aktien von VaxGen konnten heute abend um 44% zulegen nach dem der amerikanische Hersteller von flüssigen Medikamenten verkündete, dass man mit britischen Behörden darüber verhandle, wann man die Vermarktungs- und Lizenzrechte für ein Medikamenten gegen Anthrax erhalten könne. Man rechne mit einer baldigen Entscheidung.
Und dennoch verkauft heute einer der dies verschlafen oder negiert hat
in München 1600 St um 3,87 EU ????
Der verzichtet locker auf 3200 Euro......
in München 1600 St um 3,87 EU ????
Der verzichtet locker auf 3200 Euro......
*STRIKE* - Ich werde heute je nach Markt aber zumindest 50% glattstellen.
Greetinxx Heinerle2
Greetinxx Heinerle2
@frohgemut
die zu 3,87 war mal wieder ein beweis für die leistung von w:o.
gabs nicht - fehlanzeige.
gruss mbent
die zu 3,87 war mal wieder ein beweis für die leistung von w:o.
gabs nicht - fehlanzeige.
gruss mbent
Ich bin komplett raus, Schnitt >6 USD 
. Heute habe ich im frühen Geschäft noch meine Targeted Genetics verkauft - und mir mal ein paar Cerus gekauft
Greetinxx Heinerle2
(der noch EMBX, TRGNY, CLGY, DRRX, TKTX und XNVA hält)
. Heute habe ich im frühen Geschäft noch meine Targeted Genetics verkauft - und mir mal ein paar Cerus gekauft Greetinxx Heinerle2
(der noch EMBX, TRGNY, CLGY, DRRX, TKTX und XNVA hält)
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +3,07 | |
| -0,10 | |
| -4,07 | |
| +0,65 | |
| +0,96 | |
| +1,15 | |
| +2,16 | |
| -0,54 | |
| +2,41 | |
| +4,36 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 206 | ||
| 75 | ||
| 71 | ||
| 63 | ||
| 51 | ||
| 44 | ||
| 38 | ||
| 36 | ||
| 36 | ||
| 24 |
